Na Li1, Bin Zheng1, Hong-Fu Cai1, Jing Yang1, Xiao-Feng Luo2, Li-Zhu Weng3, Feng-Mei Zhan3, Mao-Bai Liu4. 1. Department of Pharmacy, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China. 2. Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. 3. School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China. 4. Department of Pharmacy, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China. liumaobai@163.com.
Abstract
BACKGROUND AND OBJECTIVE: Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is high and the medical economic burden of patients with CML on the government is heavy. This study tested the cost effectiveness of imatinib, nilotinib, and dasatinib as first-line treatment in Chinese patients who were first diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). METHODS: A state-transition Markov model combining clinical effectiveness, utility, and cost data was used. Sensitivity analyses were conducted to determine the robustness of the model outcomes. RESULTS: The imatinib-first, dasatinib-first, and nilotinib-first strategy offered patients 9.76, 9.87, and 9.72 quality-adjusted life years (QALYs) at a cost of US$303,502.42, US$381,681.03, and US$305,509.92 over 20 years, respectively. The nilotinib-first strategy exhibited the lowest utility and highest price and was thus eliminated. An incremental cost-effectiveness analysis of the imatinib-first strategy and the dasatinib-first strategy showed that the dasatinib-first strategy yielded an incremental cost-utility ratio (ICER) of 710,714.64 $/QALY compared with the imatinib-first strategy, which exceeded the threshold; hence, the dasatinib-first strategy was not cost effective and was eliminated. The results were robust for multiple sensitivity analyses. CONCLUSION: From the perspective of the Chinese medical system, imatinib is likely to be more cost effective than dasatinib and nilotinib for patients who were first diagnosed with CML-CP.
BACKGROUND AND OBJECTIVE: Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is high and the medical economic burden of patients with CML on the government is heavy. This study tested the cost effectiveness of imatinib, nilotinib, and dasatinib as first-line treatment in Chinese patients who were first diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). METHODS: A state-transition Markov model combining clinical effectiveness, utility, and cost data was used. Sensitivity analyses were conducted to determine the robustness of the model outcomes. RESULTS: The imatinib-first, dasatinib-first, and nilotinib-first strategy offered patients 9.76, 9.87, and 9.72 quality-adjusted life years (QALYs) at a cost of US$303,502.42, US$381,681.03, and US$305,509.92 over 20 years, respectively. The nilotinib-first strategy exhibited the lowest utility and highest price and was thus eliminated. An incremental cost-effectiveness analysis of the imatinib-first strategy and the dasatinib-first strategy showed that the dasatinib-first strategy yielded an incremental cost-utility ratio (ICER) of 710,714.64 $/QALY compared with the imatinib-first strategy, which exceeded the threshold; hence, the dasatinib-first strategy was not cost effective and was eliminated. The results were robust for multiple sensitivity analyses. CONCLUSION: From the perspective of the Chinese medical system, imatinib is likely to be more cost effective than dasatinib and nilotinib for patients who were first diagnosed with CML-CP.
Authors: Susan O'Brien; Ellin Berman; Hossein Borghaei; Daniel J Deangelo; Marcel P Devetten; Steven Devine; Harry P Erba; Jason Gotlib; Madan Jagasia; Joseph O Moore; Tariq Mughal; Javier Pinilla-Ibarz; Jerald P Radich; Neil P Shah Md; Paul J Shami; B Douglas Smith; David S Snyder; Martin S Tallman; Moshe Talpaz; Meir Wetzler Journal: J Natl Compr Canc Netw Date: 2009-10 Impact factor: 11.908
Authors: William V Padula; Richard A Larson; Stacie B Dusetzina; Jane F Apperley; Rudiger Hehlmann; Michele Baccarani; Ekkehard Eigendorff; Joelle Guilhot; Francois Guilhot; Rudiger Hehlmann; Francois-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Susanne Saussele; Charles A Schiffer; Richard T Silver; Bengt Simonsson; Rena M Conti Journal: J Natl Cancer Inst Date: 2016-03-04 Impact factor: 13.506
Authors: Ahmad Adel; Dina Abushanab; Anas Hamad; Mohammad Abdulla; Mohamed Izham; Mohamed Yassin Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302
Authors: Seth Rowley; Pat Garcia-Gonzalez; Jerald P Radich; Ann Kim Novakowski; Irina Usherenko; Joseph B Babigumira Journal: Cost Eff Resour Alloc Date: 2021-03-12